About Immunomedics
Immunomedics is a Healthcare company based in Morris Plains (United States) founded in 1982 by David M Goldenberg, and was acquired by Gilead in September 2020. Developer of antibodies and antibody-drug conjugates for the treatment of cancer and autoimmune diseases. The company has 358 employees. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is IMMUNOMEDICS INC. Its competitors include C4 Therapeutics, Regeneron Pharmaceuticals and Erasca; 2 of its 3 listed competitors have raised funding.
Company details
Immunomedics was founded in 1982 and is headquartered in Morris Plains, United States. Antibody-based therapeutics are developed by the company for cancer, autoimmune, and other serious diseases within the biotechnology sector. The product portfolio includes Epratuzumab targeting CD22 for acute lymphoblastic leukemia, Sacituzumab Govitecan for triple-negative breast cancer, and Govitecan for metastatic colorectal cancer, along with veltuzumab and milatuzumab for additional cancer and autoimmune applications.
- Headquarters Morris Plains, United States
- Employees 358
- Founders David M Goldenberg
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website immunomedics.com
- Social LinkedIn
- Acquired by Gilead (Sep 2020)
- Legal Name Immunomedics Inc
Funding Insights of Immunomedics
- Total Rounds 25
- Last Round Post-IPO — $75M
- First Round $802,014
(Feb 2004)
- Investors Count 3
Latest 10 of 25 funding rounds of Immunomedics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $75M | Post-IPO | – | – | |
| Jun 2017 | Post-IPO | – | – | ||
| Sep 2013 | $171,820 | Grant | – | – | |
| Aug 2013 | $213,982 | Grant | – | – | |
| Sep 2012 | $276,833 | Grant | – | – | |
| Sep 2012 | $227,025 | Grant | – | – | |
| Jan 2011 | $191,143 | Grant | – | – | |
| Jan 2011 | $191,143 | Grant | – | – | |
| Sep 2010 | $2.83M | Grant | – | – | |
| Sep 2010 | $2.83M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Immunomedics
Immunomedics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Royalty Pharma and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | gilead.com | Foster City, United States |
Investor details for Immunomedics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immunomedics
887 people are tracked at Immunomedics (560 in leadership, 9 in board & advisors, 318 in team); the tracked headcount is 358.
| Name | Role | Group |
|---|---|---|
David M Goldenberg | Founder | Leadership |
Ambika Rana | Associate Director, Data Science | Leadership |
Rebecca Gledhill | Senior Manager, People Partner EMEA | Leadership |
Rie Devert | Senior Director, Patient Safety | Leadership |
Herman Wong | Director, Global Medical Information | Leadership |
Erin Burkhart | Senior Vice President, Controller & Chief Accounting Officer | Leadership |
Cesar Garcia Gonzalez | Business Analytics Associate Director | Leadership |
Jaymin Mehta | Vice President, Global Commercial Head Of Liver, Inflammation, Covid-19, And Established Products | Leadership |
Lucy Guest | Associate Director, Regulatory Operations | Leadership |
Rajesh Ravikumar | Associate Director, Integrated Insights And Analytics | Leadership |
Vimal Unewal Supply Chain Leader | Director, Trade Operations Uk/ire | Leadership |
Joni Kane | Director | Leadership |
Henriette Burghoorn | Associate Director, Market Access | Leadership |
Christine T. | Associate Director, Disability Inclusion & Strategic Projects | Leadership |
J.c. Andry | Director, Medical Excellence - Global Medical Strategy & Operations | Leadership |
Jonathan Israel | Associate Director, Business Analytics & Commercial Excellence | Leadership |
Kristen Pela | Head Of Learning, Communications & Knowledge Management | Leadership |
Simon L. | Director, Strategic Projects, CEO Office | Leadership |
Anupam Talapatra | Global Director Of Regulatory Affairs (precision Medicine), Previously IVD Quality Business Partner | Leadership |
Kerstin Schmidt | Senior Director, Global Medical Affairs, Oncology, Genitourinary Cancers | Leadership |
867 more people are available in the full profile.
Complete people profiles for Immunomedics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Immunomedics
5 dated milestones of Immunomedics across 38 years, from founding to its latest funding, stage changes and deals.
- Founded Immunomedics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $802K.
- Funding Latest funding round, Post-IPO, of $75.0M.
- Exit Acquired by Gilead.
Competitors of Immunomedics
Immunomedics has 3 listed competitors in our database, 2 of them funded. They include C4 Therapeutics, Regeneron Pharmaceuticals and Erasca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| regeneron.com | 1988 | Tarrytown, United States | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | ||
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Immunomedics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immunomedics
Websites that share an audience with Immunomedics (immunomedics.com).
Websites whose visitors overlap most with Immunomedics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
stratech.co.uk | stratech.co.uk | 100% | #1,782,305 | – | |
immunodynamics.com | immunodynamics.com | 100% | #12,303,729 | – | |
| chemicon.com | 100% | View details | |||
| yenzym.com | 100% | #6,477,156 | View details | ||
| pdl.com | 100% | #4,031,673 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Immunomedics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Immunomedics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunomedics
Complete news archive for Immunomedics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunomedics
Immunomedics was founded in 1982 and raised its 1st funding round 22 years after it was founded.
Immunomedics is headquartered in Morris Plains, United States. It is registered at Morris Plains, New Jersey, United States.
Immunomedics has 358 employees.
Immunomedics was founded in 1982 and is headquartered in Morris Plains, United States. Antibody-based therapeutics are developed by the company for cancer, autoimmune, and other serious diseases within the biotechnology sector. The product portfolio includes Epratuzumab targeting CD22 for acute lymphoblastic leukemia, Sacituzumab Govitecan for triple-negative breast cancer, and Govitecan for metastatic colorectal cancer, along with veltuzumab and milatuzumab for additional cancer and autoimmune applications.
Immunomedics's top competitors include C4 Therapeutics, Erasca and Regeneron Pharmaceuticals.
Immunomedics has 4 investors. Key investors include Gilead, Royalty Pharma, HHS, and NEA.
Immunomedics operates through Immunomedics Inc.
Yes. Immunomedics was acquired by Gilead in September 2020.